Gyre Therapeutics, Inc. GYRE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.52M-39.5% | $37.2M+21.7% | $30.56M+14.2% | $26.77M+21.4% | $22.06M-20.9% | ||
| $1.23M-29.6% | $1.74M+7.1% | $1.63M+41.4% | $1.15M+28.7% | $894K-24.0% | ||
| $21.29M-39.9% | $35.45M+22.5% | $28.94M+12.9% | $25.62M+21.1% | $21.16M-20.7% | ||
| 94.6%-0.8pp | 95.3%+0.6pp | 94.7%-1.0pp | 95.7%-0.2pp | 95.9%+0.2pp | ||
| $6.74M+39.9% | $4.82M+104% | $2.36M-31.0% | $3.43M+10.7% | $3.1M-16.6% | ||
| $14.14M-40.6% | $23.82M+55.4% | $15.33M+0.9% | $15.19M+40.2% | $10.84M-35.7% | ||
| $7.22M+7.7% | $6.7M+55.2% | $4.32M-10.6% | $4.83M-2.5% | $4.96M-9.3% | ||
| $31.87M-14.0% | $37.08M+56.8% | $23.64M-3.9% | $24.6M+24.3% | $19.79M-27.3% | ||
| -$9.36M-8,028% | $118K-98.3% | $6.93M+219% | $2.17M-4.5% | $2.27M+242% | ||
| -41.5%-41.9pp | 0.3%-22.3pp | 22.7%+14.5pp | 8.1%-2.2pp | 10.3%+7.9pp | ||
| $29K+101% | -$2.19M-402% | $727K+601% | -$145K-236% | $107K+107% | ||
| -$9.24M— | $0-100% | $7.63M+241% | $2.24M-51.7% | $4.64M+500% | ||
| $621K-52.2% | $1.3M-23.2% | $1.69M+156% | $662K-26.5% | $901K+344% | ||
| -$8.69M— | —— | $3.61M+717% | $442K-83.6% | $2.7M— | ||
| -38.6%— | —— | 11.8%+10.2pp | 1.7%-10.6pp | 12.2%+12.2pp | ||
| -$0.10— | —— | $0.03— | $0.00— | $0.00— | ||
| -$8.68M-1,222% | $774K-89.8% | $7.57M+169% | $2.81M+0.1% | $2.81M+149% | ||
| -38.6%-40.6pp | 2.1%-22.7pp | 24.8%+14.3pp | 10.5%-2.2pp | 12.7%+8.7pp | ||
| -$9.36M-8,028% | $118K-98.3% | $6.93M+219% | $2.17M-4.5% | $2.27M+242% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gyre Therapeutics, Inc.'s revenue?
- Gyre Therapeutics, Inc. (GYRE) generated $117.0M in revenue over the trailing twelve months, up 16.3% year over year.
- Is Gyre Therapeutics, Inc. profitable?
- Gyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $1.9M over the trailing twelve months, a 6.3% net margin.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gross margin is 95.1% and operating margin is -0.1%, with a 6.3% net margin.
- What is Gyre Therapeutics, Inc.'s earnings per share?
- Gyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.07.
- Where does Gyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
